Irradiation Apparatus Manufacturing (NAICS 334517) — A U.S. Industry Primer

1. Overview

This industry makes the machines that generate and use ionizing radiation — X-rays, gamma rays, beta rays, and electron beams. In plain terms, it builds the hardware behind a CT (computed tomography) scanner in a hospital, the mammography unit at a breast-screening clinic, the X-ray baggage scanner at an airport, the linear accelerator that treats a cancer patient, and the gamma or electron-beam systems that sterilize medical supplies and inspect welds and cargo. It also makes the wear-out parts inside those machines — most importantly the X-ray tube and the digital detector. [1]

Why an investor cares: this is a high-value, technology-intensive capital-goods business. A relatively small number of U.S. plants ship roughly $9.2 billion of product a year [3], and the machines carry high price tags and long, profitable service tails. Demand is tied to durable trends — an aging population (U.S. adults 65 and older reached 61.2 million in 2024, representing 18% of the population and growing 3.1% year-over-year [18]), rising cancer diagnosis and treatment (an estimated 2.1 million new U.S. cancer cases in 2026 [19]), heavier security screening, and a regulatory push to move product sterilization away from a chemical (ethylene oxide) toward radiation. [10][15]

Public-market and private routes both exist. On public markets you can own the U.S. imaging leader (GE HealthCare), a pure-play X-ray-component maker (Varex Imaging), a radiation-therapy specialist (Accuray), a security-scanner maker (OSI Systems), and the gamma-sterilization/cobalt-60 supplier inside Sotera Health — plus foreign-listed giants (Siemens Healthineers, Philips, Canon, Fujifilm, Elekta) that dominate the equipment used in U.S. hospitals. [4][5][6][7][8][11][12] Private capital shows up in venture- and PE-backed specialists (proton-therapy makers, industrial-CT firms) and in units of larger private companies (Carestream, Analogic).

2. What it is and how it's structured

Scope. NAICS (North American Industry Classification System) code 334517 covers establishments that primarily manufacture irradiation apparatus and tubes for medical diagnostic, medical therapeutic, industrial, research, and scientific use — using beta rays, gamma rays, X-rays, or other ionizing radiation. Typical products: medical, dental, and veterinary X-ray systems; CT scanners; fluoroscopes; radiation-therapy machines (linear accelerators, CyberKnife/gamma units); X-ray tubes and flat-panel and photon-counting detectors; industrial and security X-ray/CT inspection systems; and gamma irradiators and electron-beam accelerators used for sterilization and food treatment. [1]

What it excludes (adjacent NAICS codes worth knowing):

• MRI (magnetic resonance imaging) and ultrasound machines use magnetism and sound, not ionizing radiation, and are classified under electromedical apparatus, NAICS 334510. This matters because imaging companies sell MRI and ultrasound alongside X-ray/CT, but only the radiation-based lines belong to 334517. [1]
• Sterilization services — companies that irradiate other firms' products for a fee — are not manufacturing; they sit in services codes, not 334517. The apparatus makers sell the machines; the service providers run them. [14]
• Nuclear medicine radiopharmaceuticals (the injected tracers) are pharmaceutical/chemical manufacturing, not apparatus.
• X-ray film and imaging chemicals fall under photographic/chemical manufacturing.
• Radiation-detection and monitoring instruments are generally classified under NAICS 334519, not 334517. [1]

Two-layer structure. The industry has two economically distinct layers. Component specialists produce X-ray tubes, high-voltage generators, accelerators, flat-panel or photon-counting detectors, collimators, shielding, and image-processing electronics. Systems OEMs integrate those components into a gantry, cabinet, or treatment platform, add safety controls and software, validate performance, obtain regulatory clearances, install the equipment, and support it over a long operating life. Varex describes its manufacturing as machining, fabrication, subassembly, system assembly, and final testing; it sometimes outsources subassemblies but retains design, final assembly, and testing. [6]

Ownership mix. This is a corporate, capital-intensive industry — not one of government agencies or tiny sole proprietors. It is a mix of (a) large diversified medical-technology and industrial firms, most publicly traded or units of public parents; (b) a few focused public "pure plays"; and (c) privately held specialists and PE-owned units. Federal data count 111 firms operating 121 establishments [2][3] — a small, concentrated population of mostly substantial companies. FDA analysis of 2022 Statistics of U.S. Businesses found 113 employer firms; under the applicable 1,200-employee small-business threshold, 98 firms (87%) were classified as small, though "small" under this high threshold does not mean workshop-scale. [20]

3. How big it is (federal figures)

U.S. Census Bureau data for this specific industry:

These are high-wage, high-output plants: annual payroll works out to roughly $121,000 per worker [2], and shipments to roughly $730,000 per worker [2][3] — signatures of skilled engineering and expensive hardware rather than volume assembly. A trade-association analysis using BLS QCEW data reported 13,879 employees and average annual pay of $129,646 in 2023 [21], broadly consistent with Census figures though drawing from a different source. The Small Business Administration sets an unusually high 1,200-employee cutoff for "small" here [4], a sign that even mid-size players in this field are large by normal manufacturing standards.

The undercount/mismatch caveat. The $9.18 billion figure measures product made in U.S. establishments [3] — not what Americans buy. Much of the equipment installed in U.S. hospitals is manufactured abroad by Siemens Healthineers, Philips, Canon, and Fujifilm and imported, so it never enters this count; conversely, U.S. makers export a lot. The figure is best read as domestic production, not domestic consumption. A single company illustrates the gap: GE HealthCare's global Imaging segment alone generated $9.2 billion in 2025 [5] — nearly the size of the entire domestic industry's Census shipments — because that segment includes offshore-made and non-334517 products. So federal figures reliably size U.S. factory output, but understate the market opportunity that global sales and imports create.

4. The investable universe

Unlike many primers where public plays are scarce, this industry has several — but the true pure-plays are few, and the biggest names are either diversified giants or foreign-listed.

U.S.-listed:

Foreign-listed competitors that dominate U.S. installations (accessible via foreign exchanges or ADRs):

• Siemens Healthineers (Germany) — owns Varian, the world's largest radiation-oncology maker by installed base, and a top-three imaging vendor. [12]
• Koninklijke Philips (Netherlands) and Canon Medical / Fujifilm (Japan) — the other members of the imaging "big three/five." In the U.S. medical-imaging market, GE HealthCare leads with ~40% share and the top five vendors hold ~96% combined. [11]
• Elekta (Sweden) — the #2 radiation-therapy company; fiscal 2025/26 net sales SEK 16.7 billion (~$1.7 billion), with adjusted EBIT margin of 12% and R&D spending of 12% of sales. [23]
• IBA — Ion Beam Applications (Belgium) — proton-therapy systems and industrial electron-beam/X-ray. [13]

Private and other owners: Carestream Health (X-ray, ex-Kodak), Analogic (CT and detection), Mevion Medical Systems (compact proton therapy) [13], Best Medical, and industrial-CT specialists such as North Star Imaging (part of Illinois Tool Works), Nikon, and ZEISS. Nordion's cobalt-60 franchise (inside public Sotera Health) has no direct U.S.-listed pure-play equivalent. [8]

5. How the money works

Owners make money in a razor-and-blades capital-goods model, and the recurring "blades" are where much of the profit lives.

• Big-ticket system sales. A CT scanner, linear accelerator, security CT, or industrial irradiator is a large one-time capital purchase by a hospital, imaging center, government agency, or factory. New-system revenue is lumpy and cyclical, tracking customers' capital budgets. Analysts watch orders and backlog and the book-to-bill ratio (new orders divided by revenue billed) as the leading signal of future sales. [5][12]
• Recurring aftermarket — the real annuity. X-ray tubes wear out and are replaced; detectors, service contracts, spare parts, and software upgrades follow the installed base for a decade or more. This aftermarket carries higher margins than the hardware and smooths the cycle. Service attach rate and recurring-revenue mix are the metrics to watch. CT X-ray tubes generally require replacement every two to six years, versus as long as ten years for a general-radiography tube; detectors may last seven years or more but require repair during that life. [5][6]
• Consumable sources. For gamma sterilization, the cobalt-60 radioactive source decays (about a 5.3-year half-life) and must be periodically replenished — an annuity-like consumable, though revenue can swing quarter to quarter with "harvest" schedules at the reactors that produce it. Nordion's revenue timing is a textbook example. [8]
• Components as an "arms dealer." A supplier like Varex sells tubes and detectors to many finished-equipment makers — including competitors of its own customers. This is a business-to-business volume game with thinner margins. Varex's five largest customers — Canon Medical, United Imaging, GE, Siemens Healthineers, and Rapiscan — generated about 40% of its fiscal 2025 revenue; Canon alone generated 18%, while the ten largest customers generated about 52%. [6] Those figures illustrate both OEM concentration and the bargaining leverage of major system manufacturers.

What determines profitability: gross margin (higher on service/software than hardware), R&D intensity (this industry spends heavily to stay ahead — Varex at 10.8% of revenue, Elekta at 12% [6][23]), capacity utilization and input costs (semiconductors, detector materials, cobalt-60), and the cyclicality of customer capital spending. Varex identifies copper, nickel, silver, gold, lead, tungsten, iridium, rhenium, molybdenum, rhodium, niobium, zirconium, beryllium, and high-grade steel alloys as required inputs, and relies on limited- or sole-source suppliers for transistor arrays, cesium-iodide detector coatings, specialized integrated circuits, tube targets and windows, housings, bearings, and high-voltage cables. [6] Changing a component can require redesign, requalification, and sometimes new regulatory clearance, making nominally small supply disruptions disproportionately expensive. Radiation-therapy and proton-therapy systems are the highest-ticket items; the U.S. proton-therapy market alone was about $1 billion in 2024 and is projected to reach roughly $2.5 billion by 2033. [13]

6. What drives demand

• Health care and demographics. An aging population and rising cancer incidence drive scan volumes and radiation-therapy courses, pulling through CT, mammography, molecular imaging, and linear accelerators. The U.S. population aged 65 and older reached 61.2 million in 2024 (18% of the population, up 3.1% year-over-year) [18]; the National Cancer Institute estimates 2.1 million new U.S. cancer cases in 2026 [19]. Screening programs (mammography, lung-cancer CT) add baseline demand. [10][11]
• Replacement cycles and technology jumps. Imaging hardware is typically replaced every 7–12 years, and step-changes like photon-counting CT and AI-assisted imaging pull replacement demand forward. Varex specifically identifies photon-counting detectors, lower-dose imaging, smaller linear accelerators, and improved tube life and stability as current R&D priorities. [5][6][10]
• Provider economics and reimbursement. Hospitals and imaging centers buy when capital budgets and Medicare/insurer reimbursement for scans and radiation oncology support the return on a purchase; reimbursement cuts can freeze buying. [11]
• Security spending. Airport, border, and cargo screening budgets (TSA, Customs and Border Protection) drive security X-ray and CT scanner demand; OSI Systems' Rapiscan holds large multi-year CBP contracts. TSA screened approximately 79.7 million passengers and 44.4 million checked bags in June 2025 alone, illustrating the throughput burden placed on deployed screening systems. [7][24]
• Industrial inspection. Nondestructive testing of welds, castings, electronics, batteries, and semiconductors uses industrial X-ray and CT — a growth area for Varex's Industrial segment, up 25% year-over-year in its latest quarter, including cargo-inspection systems. [6]
• Sterilization shift. Roughly half of U.S. medical-device sterilization uses ethylene oxide (a chemical carcinogen under EPA scrutiny) [15]; regulatory pressure and cobalt-60 supply constraints are pushing volume toward electron-beam and X-ray irradiation, a tailwind for irradiator makers. The global irradiation-sterilization-services market (which buys those machines) is projected to roughly double from about $2.1 billion in 2022 to $4.6 billion by 2030. [14][15]
• Cesium-irradiator replacement. The National Nuclear Security Administration's Cesium Irradiator Replacement Project supports replacement of cesium-137 blood irradiators with non-radioisotopic X-ray technology to reduce security risk [25] — favorable for X-ray irradiator manufacturers but unfavorable for suppliers dependent on sealed-source systems.

7. Regulation

This is one of the more heavily regulated corners of manufacturing, on two axes:

• FDA — product and device rules. Radiation-emitting products face dual regulation: the Electronic Product Radiation Control provisions (21 CFR Parts 1000–1050) govern radiation safety and performance, while medical devices also require premarket clearance — a 510(k) clearance (showing equivalence to an existing device) or, for higher-risk devices, PMA (premarket approval). Mammography carries an extra layer, the Mammography Quality Standards Act (MQSA) (21 CFR 900), which sets image-quality and dose standards. [16] FDA's Quality Management System Regulation (QMSR) became effective February 2, 2026, incorporating ISO 13485:2016 into the device-manufacturing framework and expanding FDA inspection access to records including management reviews and supplier audits. [26]
• NRC and Agreement States — radioactive materials. Gamma systems and cobalt-60 sources are byproduct nuclear material licensed by the Nuclear Regulatory Commission or its "Agreement State" counterparts, with post-9/11 security-of-source rules layered on top. This raises the barrier to entry for gamma/cobalt-based businesses (relevant to Nordion/Sotera). [8][27]
• Environmental and cross-cutting rules. EPA emissions rules on ethylene-oxide sterilizers (finalized 2024, then reopened for reconsideration in 2025) indirectly shape demand for radiation-based alternatives. [15] Exports of imaging and especially security-screening technology can trigger trade and export-control review; international sales require CE marking and IEC-standard compliance.

Net effect: regulation both raises barriers to entry (protecting incumbents) and creates approval and recall risk for any given product line.

8. Competitive dynamics and consolidation

The industry is moderately-to-highly concentrated. The four largest firms account for 67.5% of receipts, the top eight for 82.2%, and the top twenty for 93.4%, with a Herfindahl-Hirschman Index (a standard concentration measure) of about 1,574 [3] — the "moderately concentrated" band. In practice a handful of giants set the pace, a tier of focused specialists competes on niches, and component suppliers sell into all of them.

Consolidation has been the defining trend:

• Siemens acquired Varian (2021, ~$16 billion), making Siemens Healthineers the radiation-oncology leader. Accuray notes that new-product sales in radiation therapy are now primarily dominated by Varian (Siemens Healthineers) and Elekta. [7a][12]
• GE spun off GE HealthCare as a standalone public company (2023), the U.S. imaging leader. [5]
• Canon acquired Toshiba Medical; Philips and Fujifilm consolidated share — leaving the top five vendors with ~96% of the U.S. imaging market. [11]
• Varex itself was spun out of Varian (2017) to become the independent "arms-dealer" component supplier. [6]

Two competitive pressures are worth flagging: Chinese OEMs (United Imaging, Mindray) are climbing the value chain and competing on price globally, and component leverage means a supplier like Varex both enables and constrains the finished-equipment makers.

9. Risks

• Capital-spending cyclicality. System sales rise and fall with hospital, government, and industrial capital budgets; a reimbursement cut or budget freeze hits new-order flow quickly. The industry is not conventionally consumer-cyclical, but new-system orders are capital expenditures sensitive to interest rates, government procurement timing, and construction capacity. [11]
• Thin or negative profitability at the edges. Component and single-product players can be revenue-healthy but loss-making — Varex posted a $70 million net loss in fiscal 2025 despite growing sales [6]; radiation-therapy specialists like Accuray operate on modest margins in a market dominated by far larger rivals. [7a][12]
• Import competition and trade policy. Foreign giants dominate U.S. installations, and rising Chinese OEMs pressure price; tariffs and export controls cut both ways for domestic makers. Varex generated roughly 70% of fiscal 2025 revenue outside the United States and says tariffs and U.S.–China trade restrictions have raised material costs, encouraged localization, and made U.S.-produced equipment less competitive in some markets. [6][11]
• Supply chain and inputs. Cobalt-60 supply is constrained and reactor-scheduled [8]; detectors and systems depend on semiconductors and specialized materials. Varex identifies sole-source components and volatile specialty-metal prices as direct margin and delivery risks. [6]
• Regulatory and litigation risk. Product recalls, 510(k)/PMA delays, MQSA findings, and — for the sterilization ecosystem — ethylene-oxide-related litigation and evolving EPA rules create headline and liability risk. [15][16]
• Technology disruption. Photon-counting CT, AI, theranostics, and compact single-room proton systems can obsolete installed platforms and reset competitive positions. [13]
• Substitution risk. MRI and ultrasound can replace some diagnostic X-ray examinations; industrial ultrasound can replace radiography for some inspections; and refurbished systems can defer new-equipment purchases. In oncology, surgery, brachytherapy, chemotherapy, immunotherapy, and other drugs may substitute for or complement external-beam treatment. [7a]
• Currency and geographic concentration. Global sales expose margins to foreign-exchange swings and to demand shifts in Europe and Asia.
• Labor scarcity. The primary labor risk is scarcity and cost in engineering, software, regulatory affairs, quality assurance, and field service. Average annual pay of roughly $129,000 indicates a highly skilled workforce [21]; field-service shortages are particularly damaging because equipment downtime affects hospital throughput and can trigger penalties, warranty costs, and customer attrition.

10. How to invest and the outlook

Public-market routes.

• Broad, profitable exposure: GE HealthCare (GEHC) is the cleanest U.S.-listed way to own scale imaging (CT, X-ray, molecular imaging, mammography), though its numbers also include MRI and ultrasound outside this NAICS code. [5]
• Pure component play: Varex Imaging (VREX) is the closest thing to a pure 334517 bet — X-ray tubes and detectors sold across medical, security, and industrial end-markets — but carries the volatility and thin margins of a component supplier. [6]
• Therapy and security niches: Accuray (ARAY) for radiation oncology; OSI Systems (OSIS) for security X-ray/CT (plus healthcare and optoelectronics). [7][7a]
• Sterilization/source angle: Sotera Health (SHC) for the Nordion cobalt-60 franchise embedded in a larger sterilization-services company. [8]
• Dental and breast imaging: Dentsply Sirona (XRAY) and Hologic (HOLX) carry meaningful X-ray franchises inside broader businesses. [11][17]
• Global leaders: Siemens Healthineers, Philips, Canon, Fujifilm, Elekta, and IBA via foreign exchanges/ADRs for investors who want the dominant installed-base owners. Elekta offers relatively concentrated public radiation-therapy exposure. [12][13][23]

Reserve any judgment on share prices, dividend yields, or valuation multiples to a case-by-case look — these range from a large, profitable GE HealthCare to smaller, sometimes loss-making specialists, so they do not trade as a single "sector."

Private-market routes. Venture and growth equity back proton-therapy makers (e.g., Mevion) and industrial-CT and detector startups; private equity owns units like Carestream and Analogic; and strategic acquirers regularly roll up specialists (the Varian, Toshiba Medical, and Varex transactions show the pattern). For private investors, the durable-service-revenue and regulatory-moat characteristics that make this industry attractive are the same ones that command full valuations. The principal diligence trap is buying what appears to be a fragmented "irradiation" market without identifying where bargaining power sits: large OEM customers can dominate component suppliers, while systems vendors must fund regulatory, software, and global service infrastructure. [12]

Near-term drivers (forward-looking). The setup favors steady rather than explosive growth: an aging, cancer-diagnosing population and equipment-replacement cycles (photon-counting CT, AI) underpin imaging demand; radiation and proton therapy keep expanding, with U.S. proton-therapy revenue projected to roughly 2.5× by 2033 [13]; security-screening budgets stay firm; and the regulatory and supply-driven shift from ethylene-oxide to X-ray/electron-beam sterilization is a multi-year tailwind for irradiator makers. [14][15] The main headwinds are hospital capital-budget and reimbursement pressure, intensifying import competition, and the technology risk inherent in a field that periodically re-platforms.

---

Sources

1. U.S. Census Bureau / IBISWorld, "NAICS Code 334517 — Irradiation Apparatus Manufacturing (definition and scope)," 2024. https://www.census.gov/naics/
2. U.S. Census Bureau, "County Business Patterns (CBP), NAICS 334517," 2023 (establishments, employment, payroll). https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau, "2022 Economic Census — Industry Statistics and Concentration, NAICS 334517," 2022 (receipts, firm count, CR4/CR8/CR20/CR50, HHI). https://www.census.gov/programs-surveys/economic-census.html
4. U.S. Small Business Administration, "Table of Small Business Size Standards (NAICS 334517 = 1,200 employees)," 2023. https://www.sba.gov/document/support-table-size-standards
5. GE HealthCare Technologies Inc., Form 10-K FY2025 (total revenue $20.3B; Imaging segment $9,245M), 2026. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm
6. Varex Imaging Corporation, Form 10-K FY2025 (revenue $844.6M; gross margin 34.4%; Industrial +25% YoY; R&D $91.1M; customer concentration; component/material inputs; tube/detector replacement cycles), 2025. https://www.sec.gov/Archives/edgar/data/1681622/000168162225000108/var-20251003.htm
7. OSI Systems, Inc. / Rapiscan Systems, "Security Division and CBP contracts" (security ~59% of revenue), 2024. https://www.osi-systems.com/our-businesses/security/
8. 7a. Accuray Incorporated, Form 10-K FY2025 (revenue $458.5M; gross margin 32.1%; CyberKnife and Radixact platforms; competitive landscape and substitution risks), 2025. https://www.sec.gov/Archives/edgar/data/1138723/000119312525191242/aray-20250630.htm
9. Sotera Health Company, "Fourth-Quarter and Full-Year 2024 Results — Nordion" (Nordion net revenue $173M, +8%; cobalt-60 supply), 2025. https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-fourth-quarter-and-full-year-2024-results
10. Nordion (Sotera Health), "Cobalt-60 Supply," 2024. https://www.nordion.com/cobalt-60/cobalt-60-supply/
11. Grand View Research, "Medical Imaging Systems Market Size, Share & Trends Report," 2024. https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market
12. GM Insights / Statista, "U.S. Medical Imaging Market — vendor shares (GE HealthCare ~40%; top 5 ~96%)," 2024. https://www.gminsights.com/industry-analysis/us-medical-imaging-market
13. MarketsandMarkets / Siemens Healthineers / Elekta, "Radiotherapy Market — Siemens Healthineers (Varian) and Elekta leadership," 2024–2025. https://www.marketsandmarkets.com/ResearchInsight/radiotherapy-monitoring-devices-market.asp
14. Research and Markets, "United States Proton Therapy Market ($1B in 2024 → ~$2.5B by 2033; IBA, Varian, Hitachi, Mevion, Mitsubishi)," 2025. https://www.businesswire.com/news/home/20250121888119/en/
15. Grand View Research, "Irradiation Sterilization Services Market ($2.08B in 2022 → $4.59B by 2030)," 2023. https://www.grandviewresearch.com/industry-analysis/irradiation-sterilization-services-market-report
16. U.S. EPA / MedTech Dive, "Ethylene Oxide (EtO) Commercial Sterilizer emissions rule and 2025 reconsideration; ~50% of device sterilization uses EtO," 2024–2026. https://www.medtechdive.com/news/epa-emissions-standards-eto-medical-device-sterilizers/742435/
17. U.S. Food and Drug Administration, "Radiation-Emitting Products; Electronic Product Radiation Control (21 CFR 1000–1050); Mammography Quality Standards Act (21 CFR 900)," 2024. https://www.fda.gov/radiation-emitting-products
18. Research and Markets, "Dental Digital X-Ray Market Report 2025 — Dentsply Sirona, Envista, Varex, Planmeca, Acteon," 2025. https://www.globenewswire.com/news-release/2025/04/21/3064507/0/en/
19. U.S. Census Bureau, "Vintage 2024 Population Estimates — Older Adults (65+) reach 61.2 million, 18.0% of population," 2025. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html
20. National Cancer Institute, "SEER Cancer Statistics Factsheets — estimated 2,114,850 new U.S. cancer cases in 2026," 2026. https://seer.cancer.gov/statfacts/html/all.html
21. U.S. Food and Drug Administration, "Economic Analysis — NAICS 334517 firm counts and small-business share (Table 11)," 2024. https://www.fda.gov/media/191539/download
22. AdvaMed / Frost & Sullivan, "The Economic Impact of the Medical Technology Industry 2024 — NAICS 334517 employment and wages," 2025. https://www.advamed.org/wp-content/uploads/2025/10/Frost-Sullivan-for-AdvaMed_-The-Economic-Impact-of-the-Medical-Technology-Industry-2024.pdf
23. OSI Systems, Inc., Form 10-K FY2025 (consolidated gross margin 34.3%), 2025. https://www.sec.gov/Archives/edgar/data/1039065/000141057825001887/osis-20250630x10k.htm
24. Elekta AB, Annual Report 2025/26 (net sales SEK 16.7B; adjusted EBIT margin 12%; R&D 12% of sales), 2026. https://ir.elekta.com/files/mfn/4fee6c42-f5eb-4dff-9601-c15ca8313eec/elekta-annual-report-2025-26.pdf
25. Transportation Security Administration, "TSA Contact Center Traveler Complaints Report — June 2025" (79.7M passengers, 44.4M checked bags screened), 2025. https://www.tsa.gov/sites/default/files/foia-readingroom/tsa-contact-center-traveler-complaints-report-june-2025.pdf
26. U.S. Department of Energy / NNSA, "Cesium Irradiator Replacement Project (CIRP) Brochure," 2024. https://www.energy.gov/sites/default/files/2024-10/ORS%20Reduce%20-%20CIRP%20Brochure%20September%202024.pdf
27. U.S. Food and Drug Administration, "Quality Management System Regulation (QMSR) — effective February 2, 2026," 2026. https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
28. U.S. Nuclear Regulatory Commission, "Industrial Radiography Toolkit," 2024. https://www.nrc.gov/materials/miau/industrial-uses/rad-toolkit